Nicotinamide mononucleotide (NMN) is a precursor of the anti-aging molecule nicotinamide adenine dinucleotide (NAD+). NAD+ provides the body with the nutrients it needs to combat age-related diseases. As we age, our bodies decrease NAD+ levels. This depletion impairs the communication between our mitochondria and our nucleus, which results in a reduction in our cell’s ability to produce energy.
NMN has a wide range of pharmacological actions, including its ability to boost the level of NAD+ in the body. NMN is also believed to have a protective effect on neurovascular function. The mechanism is believed to be mediated by sirtuins, a family of molecules that regulate energy metabolism and cell survival.
NMN has been studied extensively for its effects on Alzheimer’s disease, diabetes, obesity, heart failure, and cerebral ischemia. In addition to its therapeutic effects, NMN has shown promise in supporting overall body function, including immunity and muscle performance.
Although NMN has been proven to be safe in animals, the safety of high doses is not assured for long-term administration. For this reason, further human clinical studies are needed to evaluate the safety of NMN supplementation.
However, while manufacturers have aggressively marketed NMN as an anti-aging supplement, there is no regulatory agency regulating its use. Consumer advocacy groups are calling for a more rigorous approval process, which includes assessing NMN’s effects on health and safety.
To date, no published reports have been available on the safety of NMN in humans. Human clinical trials should focus on toxicological parameters, such as the concentrations of NMN and metabolites in the human body. It is also important to assess the safety of NMN in healthy individuals.